In spite of the crisis, ELPEN, the pioneer Greek pharmaceutical industry, is dynamically dealing with the difficult circumstances faced by our country. Through its strategic growth planning, its investments in Research & Development and its worldwide presence, ELPEN supports and creates new opportunities for employment and business development.


In this context, ELPEN was distinguished by the renowned "Diamonds of the Greek Economy" institution, in an event, which took place on Wednesday, June 29th. During the ceremony, companies, which are characterized by an ability to develop amidst this crisis, deep respect for their human resources, remarkable extroversion and contribution to the national economy, were awarded.

Amidst the crisis, ELPEN managed to invest and increase its human resources up to 870 employees. In parallel, ELPEN continues to invest in the modernization of quality control and productive procedures, as well as the development of new products. In fact, the company's planning for the next 5 years includes the development of innovative drugs, with Greek patents, which will support the entrepreneurial future of both ELPEN and the Greek pharmaceutical industry on the whole, with a presence in Europe, as well as across the globe.

Mr. Vassilis Pentafragas, ELPEN's Corporate Affairs Director and PEF's Executive Consultant, received the award, and thanked on behalf of ELPEN's Board of Directors and the 870 employees of the ELPEN Group, to whom, as he emphasized, the distinction belongs. Mr. Pentafragas added: «All those who create and produce added values; all those who are being awarded today for their achievement; but also, all those who, in spite of having had their glow somewhat blurred by this crisis, continue to believe that this difficulty can turn into an opportunity for our country's future and fight to accomplish their goal; all these people deserve such a distinction. Anyone who believes in Greek scientists and entrepreneurship merits such a distinction. »

Refering to ELPEN, Mr. Pentafragas underlined the following: «At ELPEN, we choose to view the future in an optimistic manner, because we are aware of our company's potential and the potential of the Greek productive pharmaceutical industry sector. We are also aware of the prospects of domestic production. We know how to produce added values. This is why we remain in Greece; this is why we insist on daily building a better future for all of us».


  04 July 2016